An Implantable Wireless Battery-Free Selective Vagus Nerve Stimulator

This paper presents a wireless, battery-free, NFC-controlled implantable device that enables selective vagus nerve stimulation to reduce off-target side effects, demonstrating successful separation of cardiac and laryngeal fiber activation in both porcine and human trials.

The Gist

Imagine your body's nervous system as a massive, tangled bundle of fiber-optic cables running from your brain down to your organs. One of these cables is the Vagus Nerve. It's the main "internet cable" connecting your brain to your heart, lungs, stomach, and voice box.

Currently, doctors use a therapy called Vagus Nerve Stimulation (VNS) to treat conditions like epilepsy, depression, and even heart failure. Think of this like sending a signal down the cable to tell your organs to "calm down" or "work better."

The Problem:
Right now, the technology is a bit like using a firehose to water a single potted plant. When doctors stimulate the nerve, they turn on the whole cable at once. This hits everything connected to it.

• They want to tell the heart to slow down (good for heart failure).
• But the signal also hits the voice box, causing hoarseness or coughing.
• It also hits the lungs, causing shortness of breath.

Because of these annoying side effects, doctors often have to turn the volume down, which means the treatment isn't as effective as it could be.

The Solution: The "Smart Remote" for Nerves
This paper introduces a new, tiny device that acts like a precision laser pointer instead of a firehose. It's a "Selective Vagus Nerve Stimulator" (sVNS).

Here is how it works, broken down into simple concepts:

1. The "14-Channel Cuff" (The Multi-Tool)

Imagine wrapping a bracelet around the nerve. This isn't a normal bracelet; it has 14 tiny, independent electrodes spaced out around the nerve like the numbers on a clock face.

• Old way: You press a button, and all 14 electrodes fire at once.
• New way: You can pick just one electrode (or a specific group) to fire. This allows the device to target specific "bundles" of wires inside the nerve.

2. The "Wireless Battery-Free" Trick

Implanting a battery inside a body is risky; batteries leak, run out, and need surgery to replace.

• The Analogy: Think of this device like a wireless electric toothbrush. It has no battery inside. Instead, it sits in a "charging field."
• How it works: A special external device (using NFC, the same tech your phone uses to pay for coffee) sends energy and instructions through the skin. The implant catches this energy, powers up instantly, and does its job. When the external signal stops, the implant goes to sleep. This means no batteries to replace and no wires sticking out of the body.

3. The "Trial and Error" Map

Inside the nerve, the wires are organized by destination. Some wires go to the heart, some to the voice box, and some to the stomach. But we don't have a perfect map of where they are in every person.

• The Strategy: The device uses a "trial-and-error" approach. It quickly tests each of the 14 channels one by one.
• The Result: If Channel 4 makes the heart rate drop, but Channel 1 makes the voice box twitch, the doctors know exactly where to aim. They can then stimulate only Channel 4 to fix the heart without making the patient cough.

What Did They Test?

The researchers built this device and tested it in two ways:

1. Pigs: They implanted the device in pigs. By targeting specific channels, they successfully slowed the pigs' heart rates by about 23% without causing other side effects. This proved the "laser pointer" concept works.
2. A Human: They tested it on one human patient during surgery. They found that they could stimulate the heart (slowing the rate) on one side of the nerve, while the voice box stayed quiet on the other side. They even measured a clear "separation" of about 231 degrees between the heart wires and the voice wires!

Why Does This Matter?

This is a game-changer for treating Heart Failure.

• Current Limit: Doctors can't use high enough doses of VNS for heart failure because the side effects (coughing, voice changes) are too uncomfortable.
• Future Hope: With this new device, they can aim the "laser" directly at the heart wires. They can deliver a strong, effective dose to help the heart pump, while ignoring the voice wires to keep the patient comfortable.

The Catch (Limitations)

The device is currently designed for short-term use (days or weeks), like a temporary patch. It's not yet built to last for years inside the body because the silicone coating might eventually let water in and corrode the electronics. However, for testing new therapies and helping patients in the short term, it's a massive leap forward.

In Summary:
This paper presents a tiny, battery-free, wireless device that acts like a precision remote control for your vagus nerve. Instead of blasting the whole nerve and causing side effects, it lets doctors pick and choose exactly which part of the nerve to stimulate, opening the door to safer, more effective treatments for heart disease and other conditions.

Technical Summary

1. Problem Statement

Vagus Nerve Stimulation (VNS) is an established therapy for drug-resistant epilepsy and depression, with emerging potential for treating heart failure, diabetes, and rheumatoid arthritis. However, conventional VNS stimulates the entire nerve, leading to significant off-target side effects such as hoarseness, coughing, and paraesthesia. These side effects often limit the therapeutic dose that can be administered.

Current approaches to Selective VNS (sVNS)—which aims to stimulate specific nerve fascicles to target specific organs while avoiding others—rely on large, non-implantable benchtop systems (e.g., ScouseTom) or complex switching arrays. There is a critical lack of miniaturized, implantable, battery-free devices capable of delivering spatially selective stimulation for short-to-medium-term preclinical and clinical trials. Furthermore, long-term implantable devices face reliability challenges due to battery failure, lead degradation, and the harsh physiological environment.

2. Methodology

The authors designed, manufactured, and tested a 15-channel, wirelessly powered, battery-free sVNS system.

• System Architecture:

  • Power & Communication: The device utilizes Near-Field Communication (NFC) at 13.56 MHz for both power harvesting and data transmission. An external NFC transmitter powers the implant and sends stimulation parameters.
  • Hardware: The system uses off-the-shelf components to minimize cost and size. Key components include an NFC IC (NT3H2211) for power/data, a boost regulator (LT8410) to generate a 20 V supply, and a microcontroller (EFM8 Sleepy Bee).
  • Stimulation Output: A custom 14-channel multielectrode cuff array (plus 1 full-nerve channel) surrounds the nerve. The electrodes are arranged circumferentially to allow longitudinal current steering. The system delivers charge-balanced biphasic square wave pulses.
  • Specifications:
    • Max Current: ~2 mA (adjustable in 32 µA steps).
    • Pulse Width: 50 µs to 4 ms.
    • Frequency: 1–50 Hz.
    • Voltage Compliance: ±20 V (to handle high tissue impedance).
    • Size: Ø33.73 mm.

• Fabrication & Encapsulation:

  • The PCB and electrode array were encapsulated in biocompatible silicone (MED-4220) using a custom 3D-printed mold and injection molding technique to ensure hermetic sealing for short-term implantation.
  • Accelerated aging tests were conducted in phosphate-buffered saline at 67°C to estimate in vivo durability.

• Experimental Design:

  • Porcine Trial (n=4): The device was implanted on the cervical vagus nerve. A "trial-and-error" protocol stimulated channels sequentially (30s on, 30s off) to map cardiac efferent fibers. Heart rate (HR) was monitored via invasive pressure recordings.
  • Human Pilot (n=1): A modified non-implantable but portable version was used during surgery on a patient scheduled for standard VNS implantation. The device was placed on the left vagus nerve. Surface EMG (laryngeal activity) and HR were recorded to map cardiac efferent vs. afferent fibers and laryngeal motor fibers.

3. Key Contributions

1. First Implantable Battery-Free sVNS Device: The paper presents the first fully implantable, wireless, battery-free stimulator specifically designed for spatially selective vagus nerve stimulation.
2. Miniaturization & Cost: The device is built using off-the-shelf components, resulting in a low manufacturing cost (~$97 for PCB assembly) and a compact form factor suitable for acute animal and human trials.
3. Open Source: The hardware design files, firmware, and GUI are made publicly available to facilitate replication and further research.
4. Validation of Organotopy: The study provides in vivo evidence that specific fascicles of the vagus nerve can be selectively recruited to modulate specific organs (heart vs. larynx) without activating the entire nerve.

4. Results

• Benchtop Performance:

  • The device successfully delivered current with a maximum error of 3.83% for amplitude and 10.88% for pulse width.
  • It achieved seamless channel switching in <100 µs.
  • Wireless power transfer was stable up to a 10 mm coil-to-coil distance.
  • Mean power consumption was 11.9 mW.

• Accelerated Aging:

  • Devices survived up to 15 days in accelerated aging (equivalent to ~100 days in vivo based on Arrhenius modeling).
  • Failures were attributed to corrosion at antenna terminals, indicating the need for improved hermetic packaging for chronic long-term use (years).

• Porcine In Vivo Results:

  • Selective stimulation achieved a mean bradycardia of 23.28 ± 12.91%.
  • The device performed comparably to the large benchtop ScouseTom system (no statistically significant difference in HR reduction).

• Human Pilot Results:

  • Cardiac Selectivity: Stimulation of channels 8–10 caused a 7.5% decrease in HR (cardiac efferent activation), while channels 1–7 and 11–14 caused a slight HR increase (cardiac afferent activation).
  • Laryngeal Selectivity: Laryngeal evoked potentials (EMG) were strongest at channels 1–4 and weakest at channel 12.
  • Spatial Separation: The study observed a 231° separation between the regions of cardiac efferent fibers and laryngeal fibers, confirming that therapeutic cardiac stimulation can be achieved while minimizing laryngeal side effects.

5. Significance

This work demonstrates a viable pathway toward precision neuromodulation. By enabling the selective stimulation of specific vagal fascicles, clinicians can potentially:

• Enhance Therapeutic Efficacy: Deliver higher, more effective doses to target organs (e.g., heart for heart failure) without triggering side effects.
• Reduce Side Effects: Avoid activating fibers responsible for hoarseness or coughing.
• Improve Safety: The battery-free, wireless design eliminates risks associated with battery leakage and the need for surgical battery replacements.

While the current device is suitable for acute and medium-term studies, the authors note that future iterations must address packaging robustness (e.g., hermetic ceramic sealing) to support chronic, long-term implantation. This technology lays the groundwork for next-generation VNS therapies for heart failure and other autonomic disorders.